Novozymes consolidates cell-culture ingredients activities

Novozymes Biopharma is taking another step towards building critical mass within key business areas by moving all its activities in Adelaide, Australia, to Novozymes’ sites in Bagsværd, Denmark and Nottingham, England.

This consolidation will streamline the company’s research and development setup within industrial cell culture ingredients and allow for a more focused and cost effective approach to the market.

The reorganization will result in layoffs in Australia.

It is anticipated that the majority of the changes will be completed by the end of 2010.